Laurel Wealth Advisors Inc. boosted its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 2.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,757 shares of the pharmaceutical company’s stock after buying an additional 697 shares during the quarter. Laurel Wealth Advisors Inc.’s holdings in GlaxoSmithKline PLC were worth $1,196,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Bingham Osborn & Scarborough LLC purchased a new position in GlaxoSmithKline PLC in the 2nd quarter worth about $311,000. 10 15 Associates Inc. raised its position in GlaxoSmithKline PLC by 6.4% in the 1st quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares during the last quarter. Lincluden Management Ltd. raised its position in GlaxoSmithKline PLC by 1.7% in the 1st quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares during the last quarter. Anchor Capital Advisors LLC raised its position in GlaxoSmithKline PLC by 9.6% in the 1st quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares during the last quarter. Finally, Freestone Capital Holdings LLC raised its position in GlaxoSmithKline PLC by 11.9% in the 2nd quarter. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company’s stock worth $4,054,000 after buying an additional 10,017 shares during the last quarter. 9.28% of the stock is owned by institutional investors and hedge funds.

Shares of GlaxoSmithKline PLC (GSK) remained flat at $40.61 on Monday. 2,671,227 shares of the company traded hands. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.53. The company’s 50 day moving average price is $40.07 and its 200-day moving average price is $41.64. The stock has a market cap of $99.25 billion, a P/E ratio of 39.35 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a dividend of $0.491 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.84%. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Holdings Boosted by Laurel Wealth Advisors Inc.” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/09/glaxosmithkline-plc-gsk-holdings-boosted-by-laurel-wealth-advisors-inc.html.

Several research firms have recently commented on GSK. Argus reaffirmed a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Tuesday, July 18th. TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. Finally, Citigroup Inc. lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $44.67.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.